Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, Wellington Management, as well as multiple large investment.
Avidity Biosciences (NASDAQ:RNA – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a note issued to investors on Thursday, Benzinga reports. They presently have a $35.00 price objective on the biotechnology company’s stock. Needham & Company LLC’s target price indicates a potential upside of 129.36% […]
As of Feb. 29, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Avidity Biosciences (RNA) Buy Rating Reaffirmed at Chardan Capital themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.